The therapeutic potential of psychedelic drugs: past, present, and future

Psychedelic compounds such as psilocybin and LSD have a long history of medicinal and ritual use, and they were widely investigated by psychiatrists and psychologists from the 1950s until prohibitive legislation in the mid-1960s halted much formal research. After a roughly 25-year hiatus, human research into psychedelics resumed in the early 1990s and has since produced neuroimaging, psychopharmacology, and early-phase clinical studies. These contemporary reports include small trials of psilocybin and LSD for conditions such as obsessive–compulsive disorder, addiction, end-of-life distress, and major depressive disorder, together with modern brain-imaging work. This paper is a circumspective commentary in which Carhart-Harris and Goodwin set out contrasting but convergent perspectives on the therapeutic potential of psychedelics, with particular attention to developing psilocybin as a treatment for depression. Carhart-Harris offers a cautiously optimistic account emphasising potential advantages over conventional antidepressants, while Goodwin provides a more sceptical appraisal focused on patient selection, trial design, and evidential limitations. The authors jointly discuss the current evidence base, mechanisms of action, methodological challenges, and recommendations for future clinical development.

The extracted text does not describe a formal methods section because the paper is a narrative, opinion-led review rather than a systematic review or original empirical study. Instead, the article synthesises historical material and recent human research findings and presents two authored viewpoints: a ‘tempered optimism’ by Carhart-Harris and an ‘upbeat pessimism’ by Goodwin, followed by a joint discussion on how to advance the field. Evidence drawn into the commentary includes early mid-twentieth-century case series and non-randomised studies, later meta-analyses of historical trials (for example, studies from 1949–1973 and LSD trials for alcoholism), modern double-blind randomised controlled work in healthy volunteers (a 2006 DB-RC comparing high-dose psilocybin and methylphenidate), recent small clinical trials in various patient groups, and neuropharmacological and neuroimaging findings relating to serotonergic receptor action. The authors also critique design features of specific contemporary trials—most notably two crossover trials of psilocybin in cancer patients—and draw on trial outcomes, sample characteristics (including rates of prior hallucinogen use), and methodological problems such as blinding, outcome measurement, and medication interactions to formulate recommendations for future trials.

The narrative review highlights several strands of empirical evidence and methodological observations from past and recent studies. Early uncontrolled work reported large apparent benefits: a meta-analysis of 19 studies conducted between 1949 and 1973 found that 79% of patients showed a clinically judged improvement after psychedelic-assisted treatment, and separate meta-analytic work from the 1950s–60s supported LSD's potential for alcoholism. These historical studies lacked standardised diagnostics, severity measures, randomisation, and controls. Modern controlled studies are smaller but more rigorous. A 2006 double-blind randomised controlled trial in healthy volunteers found greater improvements in psychological wellbeing at two months after a single 30 mg dose of psilocybin compared with 40 mg methylphenidate; more than half of those receiving psilocybin rated the experience among the most personally meaningful of their lives. Early-phase clinical trials have reported outcomes consistent with potential efficacy for conditions including obsessive–compulsive disorder, end-of-life psychological distress, alcohol and tobacco dependence, and major depressive disorder, but most of these trials have small sample sizes and were primarily designed to assess safety and tolerability rather than definitive efficacy. The two independently conducted crossover trials in cancer-related distress warrant particular scrutiny. Both compared low-dose or active placebo conditions with high-dose psilocybin and reported marked acute subjective effects on the high dose, including anxiety, tearfulness and occasional paranoid ideation. Blinding was likely compromised because the high-dose effects are florid and obvious to participants; this creates the possibility of demand characteristics influencing subjective outcomes and third-party reports. In one trial, prior recreational hallucinogen use among participants was high (reported as 55%), raising concerns about sample representativeness and expectation bias. Other empirical and practical points reported include: SSRIs and other antidepressants that downregulate 5-HT2A receptors may attenuate psilocybin's acute and putative therapeutic effects, implying medication washout may be necessary; psilocybin's pharmacology contrasts with SSRIs (psychedelics act as 5-HT2A agonists and tend to heighten emotional sensitivity, whereas SSRIs affect post-synaptic 5-HT1A signalling and often blunt emotional responsiveness); and objective outcome measures (for example, passive geolocation or activity monitoring) might complement subjective symptom ratings and reduce bias in future trials. Suggestions for trial design emerging from the synthesis include a multiple-dose randomised trial (for example 1 mg, 10 mg, 25 mg) to provide an active low-dose comparator and to reduce the ethical and recruitment difficulties of a true inert placebo. Treatment-resistant depression (TRD) is proposed as a logical initial clinical indication for more definitive trials, though Carhart-Harris advocates evaluation earlier in the illness course as well. Comparative trials versus other rapid-acting agents such as ketamine, investigation of dose and psychological support components, and economic evaluations of cost-effectiveness are further priorities noted by the authors.

Carhart-Harris interprets the accumulated evidence with cautious optimism, arguing that psilocybin—combined with psychological support—may become an early and clinically valuable option for depression. He emphasises putative advantages such as rapidity and durability of effect, minimal dosing burden, a favourable side-effect profile, and an approach that may work by processing rather than suppressing aversive memories and emotions. Carhart-Harris also highlights the importance of the acute psychedelic experience, noting that aspects of that experience have been predictive of longer-term outcomes in some studies. Goodwin offers a more reserved perspective, stressing methodological and practical challenges that temper enthusiasm. He questions whether certain patient groups studied to date, such as cancer patients with existential distress, represent a clear unmet need or are prone to selection biases (for example, high prior hallucinogen use and an intrinsic interest in psychedelic experiences). He also emphasises problems with crossover designs and the difficulty of maintaining blinding when active doses produce unmistakable subjective effects, which in turn raises the risk of demand characteristics affecting self- and third-party-reported outcomes. Goodwin recommends greater use of objective outcome measures where feasible and careful attention to trial populations and endpoints. Both authors agree on several core points for future research. High-quality randomised trials are required, with careful consideration of patient selection (TRD is viewed as a sensible starting point), medication washout procedures because SSRIs may blunt psilocybin effects, and the need to define the role and extent of psychological support. They propose pragmatic designs such as dose-ranging arms (1 mg, 10 mg, 25 mg) to provide an active low-dose comparator and to reduce placebo-related recruitment problems, and suggest comparative studies against other rapid-acting interventions like ketamine. The investigators also acknowledge limitations in the existing literature—small sample sizes, subjective outcome measures, potential unblinding, sample representativeness issues, and interactions with ongoing psychotropic medication—and call for economic analyses to assess cost-effectiveness given the resource implications of supervised psychedelic-assisted sessions. Overall, the authors position psychedelics as a promising but still early-stage therapeutic avenue that requires rigorous clinical trials, methodological care, and regulatory engagement before its true therapeutic value and implementation parameters can be established.